| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF15 |
| Uniprot No | O95150 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 72-251aa |
| 氨基酸序列 | LKGQEFAPSHQQVYAPLRADGDKPRAHLTVVRQTPTQHFKNQFPALHWEHELGLAFTKNRMNYTNKFLLIPESGDYFIYSQVTFRGMTSECSEIRQAGRPNKPDSITVVITKVTDSYPEPTQLLMGTKSVCEVGSNWFQPIYLGAMFSLQEGDKLMVNVSDISLVDYTKEDKTFFGAFLL |
| 预测分子量 | 25.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF15(TL1A)重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**: *"TL1A (TNFSF15) regulates IFN-γ production in human T cells"*
**作者**: Migone TS 等
**摘要**: 研究通过重组TNFSF15蛋白分析其与T细胞表面受体DR3的相互作用，发现其能够增强T细胞中IFN-γ的分泌，提示其在Th1免疫应答中的调控作用。
2. **文献名称**: *"Recombinant TNFSF15 protein attenuates murine colitis by modulating dendritic cell function"*
**作者**: Wang EC 等
**摘要**: 通过表达重组TNFSF15蛋白，研究发现其在小鼠结肠炎模型中通过抑制树突状细胞的促炎活性，减轻肠道炎症反应，表明其潜在的治疗炎症性肠病(IBD)的应用价值。
3. **文献名称**: *"Structural and functional analysis of TNFSF15 in autoimmune diseases"*
**作者**: Jin S 等
**摘要**: 利用重组TNFSF15蛋白解析其晶体结构，揭示其与DR3受体结合的关键区域，并通过体外实验证明其异常表达与类风湿性关节炎中T细胞活化的相关性。
4. **文献名称**: *"TNFSF15 modulates angiogenesis through VEGF pathway in endothelial cells"*
**作者**: Kim S 等
**摘要**: 研究发现重组TNFSF15蛋白可通过抑制VEGFR2磷酸化阻断血管内皮细胞增殖，提示其在抑制肿瘤血管生成中的潜在机制。
以上研究涵盖了TNFSF15重组蛋白在免疫调控、疾病模型、结构功能及血管生成中的多方向应用。
TNFSF15 (Tumor Necrosis Factor Superfamily Member 15), also known as TL1A (TNF-like ligand 1A), is a cytokine encoded by the TNFSF15 gene. It plays a critical role in modulating immune responses and inflammatory processes, particularly through interactions with its cognate receptor DR3 (Death Receptor 3). Structurally, TNFSF15 exists as a type II transmembrane protein that can be proteolytically processed into a soluble form. Its recombinant version is typically produced in heterologous expression systems (e.g., Escherichia coli, mammalian cells) to ensure proper folding and bioactivity.
Functionally, TNFSF15 regulates T-cell activation, differentiation, and apoptosis, and is implicated in autoimmune and chronic inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis, and psoriasis. It activates downstream signaling pathways, including NF-κB and MAPK, influencing cytokine production and immune cell recruitment. Recombinant TNFSF15 protein serves as a vital tool for studying these mechanisms in vitro and in vivo.
Therapeutically, targeting the TNFSF15-DR3 axis has gained attention. Antagonists (e.g., monoclonal antibodies) are being explored to dampen pathological inflammation, while agonists may enhance anti-tumor immunity. Preclinical studies highlight its dual role in promoting or suppressing inflammation depending on context, underscoring its complexity. Clinical trials investigating anti-TL1A therapies for IBD and other conditions are underway, reflecting its translational potential. Overall, TNFSF15 recombinant protein bridges basic research and therapeutic innovation in immune-mediated diseases.
×
